Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage?
- PMID: 2357767
- DOI: 10.1007/BF02897199
Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage?
Abstract
Despite clear evidence that the effective penetration of the anthracycline antibiotics into experimental tumors or multicell spheroids is poor, these drugs exhibit clinical activity against a variety of solid tumors. In an attempt to understand this apparent contradiction, we used the Chinese hamster V79 spheroid system and flow cytometry techniques for intra-spheroid pharmacological studies of doxorubicin and daunomycin. Our results indicate that the slow delivery of the anthracyclines to the inner cells of spheroids is due to the rapid binding of the drug by cells in the outer layers. After exposure, the anthracyclines are retained much more effectively when cells remain in intact spheroids than when the spheroids have been dispersed, resulting in considerably more cytotoxicity in situ. This result indicates a need for considerable caution in attempting to predict the anti-tumor efficacy of drugs by using either conventional cell-culture systems, spheroids that have been disaggregated immediately post-exposure, or excision assays of tumors from experimental animals. Furthermore, our results suggest the need for a critical evaluation of the significance of the multidrug resistance (MDR) phenotype for cells surrounded by other drug-containing cells as opposed to single cells in drug-free culture medium.
Similar articles
-
Chemosensitivity testing in V79 spheroids: drug delivery and cellular microenvironment.J Natl Cancer Inst. 1986 Jul;77(1):247-52. J Natl Cancer Inst. 1986. PMID: 2425117
-
In vitro chemosensitivity testing using the multicellular tumor spheroid model.Cancer Drug Deliv. 1987;4(2):63-74. doi: 10.1089/cdd.1987.4.63. Cancer Drug Deliv. 1987. PMID: 3427553
-
Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro.Cancer Res. 1981 Sep;41(9 Pt 1):3495-8. Cancer Res. 1981. PMID: 7260912
-
Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.J Clin Pharmacol. 1986 Sep-Oct;26(7):491-509. doi: 10.1002/j.1552-4604.1986.tb02942.x. J Clin Pharmacol. 1986. PMID: 2944917 Review.
-
Anthracyclines.Cancer Chemother Biol Response Modif. 1990;11:45-57. Cancer Chemother Biol Response Modif. 1990. PMID: 2223402 Review.
Cited by
-
Effect of wall compliance and permeability on blood-flow rate in counter-current microvessels formed from anastomosis during tumor-induced angiogenesis.J Biomech Eng. 2012 Apr;134(4):041003. doi: 10.1115/1.4006338. J Biomech Eng. 2012. PMID: 22667678 Free PMC article.
-
Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids.Cancer Chemother Pharmacol. 1992;29(5):343-53. doi: 10.1007/BF00686002. Cancer Chemother Pharmacol. 1992. PMID: 1551172
-
Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs.J Biol Inorg Chem. 2015 Oct;20(7):1081-95. doi: 10.1007/s00775-015-1290-2. Epub 2015 Sep 1. J Biol Inorg Chem. 2015. PMID: 26323351 Free PMC article.
-
The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models.Br J Cancer. 2003 Oct 20;89(8):1581-9. doi: 10.1038/sj.bjc.6601300. Br J Cancer. 2003. PMID: 14562035 Free PMC article.
-
Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000.Cancer Biol Ther. 2019;20(9):1258-1269. doi: 10.1080/15384047.2019.1617570. Epub 2019 May 26. Cancer Biol Ther. 2019. PMID: 31131698 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources